Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development
about
Feedback Regulation of Kinase Signaling Pathways by AREs and GREsA novel high throughput biochemical assay to evaluate the HuR protein-RNA complex formationCalcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes.TGFβ- and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR)HuR function in disease.Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progressionTristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma.α-Tocopheryl phosphate--an activated form of vitamin E important for angiogenesis and vasculogenesis?Increased synthesis of folate transporters regulates folate transport in conditions of ethanol exposure and folate deficiency.Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy.Post-transcriptional regulation of cytokine and growth factor signaling in cancer.C/EBPβ and Nuclear Factor of Activated T Cells Differentially Regulate Adamts-1 Induction by Stimuli Associated with Vascular Remodeling.Protein kinase C activation affects, via the mRNA-binding Hu-antigen R/ELAV protein, vascular endothelial growth factor expression in a pericytic/endothelial coculture model.Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression.Emerging role of HuR in inflammatory response in kidney diseases.Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma.Regulation at multiple levels control the expression of folate transporters in liver cells in conditions of ethanol exposure and folate deficiency.
P2860
Q26773059-4F45825E-2FDC-4E32-8316-6D8CEC8EA512Q28535252-5BD62EEC-D991-40F0-9461-79AC3C843A29Q34009025-ABCEE8FB-84C1-4BB2-9F7E-D9FB2D342401Q34515338-F4A1CED4-1C27-41B4-88EE-E4BCA8113441Q35041204-C9A4D289-C036-4031-9179-1B0D8F23114BQ35966719-7B2E3D87-3780-4A16-BC05-02244FF657EEQ35973628-6AB37DAC-BA62-4BC9-A153-C797C1BEA74DQ36616576-9ADE8BD7-AC99-4FFE-9876-4359C6E15649Q37979127-858240C7-FFBF-4FBE-9DB8-6BD9419CD4ACQ38830478-53DA95F9-44F6-412F-A395-D0D8AEC54B06Q38895113-B0668CE2-4074-453B-8BC2-36FC8FD98660Q39036700-3322A58A-6AEA-48BB-A0F3-37C2CD65E10CQ40689085-71812CEA-3606-4FA8-A216-BD33DEED6449Q42268509-D96155A3-ABC5-4B27-A5E4-CC0E2F1E6937Q42559398-AF343BD3-1585-45BB-99DF-D1F9FB65FD0AQ47801949-ADC41EDC-F011-40D8-8DF0-14658BCFA86AQ52943366-4856D51D-38C6-436C-85BE-B01E3C2D9E8BQ53627902-4F03313D-981C-40C8-8690-EC7185BA893E
P2860
Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Altered VEGF mRNA stability fo ...... cations for cancer development
@ast
Altered VEGF mRNA stability fo ...... cations for cancer development
@en
Altered VEGF mRNA stability fo ...... cations for cancer development
@nl
type
label
Altered VEGF mRNA stability fo ...... cations for cancer development
@ast
Altered VEGF mRNA stability fo ...... cations for cancer development
@en
Altered VEGF mRNA stability fo ...... cations for cancer development
@nl
prefLabel
Altered VEGF mRNA stability fo ...... cations for cancer development
@ast
Altered VEGF mRNA stability fo ...... cations for cancer development
@en
Altered VEGF mRNA stability fo ...... cations for cancer development
@nl
P2093
P2860
P356
P1476
Altered VEGF mRNA stability fo ...... cations for cancer development
@en
P2093
Aninda Basu
Dipak Datta
Soumitro Pal
P2860
P304
25196-25202
P356
10.1074/JBC.M110.119446
P407
P577
2010-06-16T00:00:00Z